Would a rare disease researcher have an advantage with EB-2 NIW?

Potentially, yes. In the EB-2 NIW, a rare disease researcher tends to start from a strong position, because the subject matter often connects directly with the national interest: public health, scientific innovation, and complex fields where advances bring broad benefit to society. This helps support the argument that the work has merit and national importance.

That said, the topic alone guarantees nothing. The pathway evaluates each case on its own merits, not the label of the field. The advantage only materializes when you can demonstrate that your research generates knowledge and solutions with real, sustained impact, not merely that you work in a relevant area.

To turn that potential into a strong case, evidence such as the following tends to carry weight:

• Publications in recognized journals and citations of your work by other researchers.
• Patents, collaborations, and recognition tied to your work.
• Signals of continuity and sustained impact from your line of research.

Because each case is evaluated individually, the most productive approach is to gather robust evidence and shape your strategy with a specialist, and to verify the current criteria with the official source before filing.

About the author

Victoria Harper

Editor-in-Chief

Meet the author

As a journalist and lead editor at Visto n’ Visa, Victoria helps ensure that immigration topics are covered in a clear, trustworthy, and easy-to-understand way. Her focus is on delivering useful, human, and relevant content for people exploring new paths abroad.